Showing results (111-120 of 142) with videos related to

Sort By:
Pageof 15
AIDS (London, England)|October 13, 2023
Bridging the gap: identifying factors impacting mRNA severe acute respiratory syndrome coronavirus 2 vaccine booster response in people with HIV-1Frédérique Chammartin, Alexandra Griessbach, Katharina Kusejko, et al.
AIDS (London, England)|August 19, 2021
Neurocognitive course at 2-year follow-up in a Swiss cohort of people with well-treated HIVJosé Damas, Bruno Ledergerber, Isaure Nadin, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 30, 2020
Telomere Length, Traditional Risk Factors, Factors Related to Human Immunodeficiency Virus (HIV) and Coronary Artery Disease Events in Swiss Persons Living With HIVTanja Engel, Marieke Raffenberg, Isabella C Schoepf, et al.
Open Forum Infectious Diseases|September 23, 2022
Anticholinergic and Sedative Medications Are Associated With Neurocognitive Performance of Well Treated People With Human Immunodeficiency VirusBernadette Jakeman, Alexandra U Scherrer, Katharine E A Darling, et al.
Plos One|March 2, 2021
Alcohol consumption and neurocognitive deficits in people with well-treated HIV in SwitzerlandKatharine E A Darling, Isabella Locatelli, Nadia Benghalem, et al.
British Journal of Haematology|November 16, 2022
Antibody response to a third SARS-CoV-2 vaccine dose in recipients of an allogeneic haematopoietic cell transplantationAndriyana K Bankova, Chloé Pasin, Alice Huang, et al.
Transplantation and Cellular Therapy|January 29, 2022
Antibody Response to SARS-CoV-2 Vaccination in Patients following Allogeneic Hematopoietic Cell TransplantationAlice Huang, Caroline Cicin-Sain, Chloe Pasin, et al.
The Journal of Infectious Diseases|December 15, 2021
Telomere Length Declines in Persons With Human Immunodeficiency Virus Before Antiretroviral Therapy Start but Not After Viral Suppression: A Longitudinal Study Over >17 YearsIsabella C Schoepf, Christian W Thorball, Bruno Ledergerber, et al.
AIDS (London, England)|July 25, 2022
Determinants of antibody response to severe acute respiratory syndrome coronavirus 2 mRNA vaccines in people with HIVFrédérique Chammartin, Katharina Kusejko, Chloé Pasin, et al.
Pageof 15